The researchers report that they have designed molecular inhibitors that target specific proteins associated with Alzheimer's disease and HIV to prevent them from forming amyloid fibres, the elongated chains of interlocking proteins that play a key role in more than two dozen degenerative and often fatal diseases.
"By studying the structures of two key proteins that form amyloids, we were able to identify the small chain of amino acids responsible for amyloid fibre formation and engineer a 'molecular cap' that attaches to the end of the fibres to inhibit their growth," said research leader David Eisenberg, director of the UCLA-Department of Energy Institute of Genomics and Proteomics and a Howard Hughes Medical Institute investigator.
The study was published online June 15 in the journal Nature and will be available in an upcoming print edition.
"This research is an important first step toward the development of structure-based drugs designed against amyloid diseases," said Eisenberg, who is a UCLA professor of chemistry, biochemistry and biological chemistry and a member of the California NanoSystems Institute at UCLA. "Our results have opened up an avenue so that universities and industry can start creating therapeutics that could not have been produced 10 years ago."
Amyloid fibres are elongated, water-tight structures formed from two linked protein sheets. Proteins from each sheet contribute side chains, causing them to interlock like the teeth of a zipper, Eisenberg said.
The fibres are found not only Alzheimer's disease but in a variety of conditions, including Lou Gehrig's disease, Parkinson's disease, type II diabetes and a family of disorders related to mad cow disease, among others. In Alzheimer's and other neurodegenerative diseases, the tau protein forms amyloid fibres inside brain cells, destroying them through a mechanism that is still being investigated.
Though many serious diseases are characterised by amyloid fibres, Alzheimer's is the most prevalent, Eisenberg said. Today there are 5 million patients in the US who suffer from Alzheimer's, with 500 000 new cases every year. Alzheimer's health care cost this year alone have been estimated at $178 billion, including the value of unpaid care for Alzheimer's patients provided by nearly 10 million family members and friends.
"By the year 2050, it is projected that there will be 19 million Alzheimer's patients," Eisenberg said. "The care of so many patients with this debilitating illness could be a substantial fraction of the gross domestic product of the United States."
Eisenberg and his research team found that of the entire tau protein, a small chain of just six amino acids - abbreviated VQIVYK - was responsible for the formation of amyloid fibres. By studying the structure of the fibres using microcrystallography, a method developed at UCLA for this research, the team was able to use the fibres as a template to design an inhibitor that could 'cap' the fibre and stop it from growing.
The results were dramatic. The introduction of the inhibitor into a tau protein solution completely prevented amyloid fibre formation, validating the idea that the structure-based design of therapeutics for amyloid diseases is a plausible option.
Despite this success, there is still a long road ahead before a viable therapeutic can be developed to combat the onset of Alzheimer's in human patients, Eisenberg said. The inhibitor, a chain of amino acids, is far too large to penetrate deep into the brain where the tau proteins form amyloid fibres.
"This research is an important step toward identifying smaller molecules that can be utilised to develop a therapeutic," Eisenberg said. "Our goal is to be able to delay the onset of Alzheimer's disease."
Unlike the tau protein, the SEVI (semen-derived enhancer of viral infection) protein is a far more accessible target for a molecular blocker because it builds amyloid fibres in a vaginal environment, a key process in the sexual transmission of HIV, Eisenberg said.
"The presence of SEVI makes the rate of HIV infection through sexual transmission up to 100 000 times more likely," he said. "By blocking SEVI, we have a method for inhibiting the sexual transmission of HIV."
Though the tau and SEVI proteins have different structures and unrelated functions, they both form amyloid fibres with similar morphology, making it possible to design two separate inhibitors using the same process, according to Eisenberg.
The SEVI blocker proved to be equally effective in preventing fibre growth, bolstering the idea that blockers can be designed for other diseases associated with amyloid fibres as well.
"Though many tests remain, it seems we could be on the way to developing a therapeutic," Eisenberg said. "Our hope is that we could make a blocker that could be applied with a vaginal gel or spray that would help to prevent HIV infection."
The tau and SEVI protein inhibitors were designed using synthetic amino acids, similar to the standard protein building blocks of the human body. However, these synthetic amino acids were flipped, as if viewed in a mirror, or had added side chains not normally found in nature. Enzymes in the human body that are programmed to break apart protein-like chains are, in principle, unable to recognise the non-natural amino acids, keeping the blockers safe to latch on to the target proteins.
This research was federally funded by the National Institutes of Health, the National Science Foundation and the US Department of Energy, as well as by the Howard Hughes Medical Institute and the Joint Centre for Translational Medicine.
Other co-authors of this study included UCLA postdoctoral scholars Stuart Sievers and Lin Jiang; UCLA graduate students Howard Chang and Anni Zhao; John Karanicolas, an assistant professor at the University of Kansas; Jason Stevens, an undergraduate at the University of Kansas; David Baker, a professor at the University of Washington; and professor Jan Münch and researcher Onofrio Zirafi, of the University of Ulm in Germany.
A second research team also led by Eisenberg recently announced that it had identified four small molecules that bind to amyloid fibres, including a promising candidate called 'orange-G' that wedges into the zipper-like fibre and may be able to break it apart.
This study was published 14 June in PLoS Biology, an online journal of the Public Library of Science.
"These are the first small molecules visualised as they bind to amyloid-like fibres," Eisenberg said. "These small molecules are less likely to be broken up in the body and can potentially be modified to force apart amyloid fibres or serve as diagnostic tools to identify infected areas of the body."
Eisenberg and his research team found that orange-G was uniquely able to pierce the impenetrable "steric zippers" that seal the water-tight amyloid fibres of the amyloid-beta protein that is responsible for forming senile plaques in Alzheimer's disease.
"In 10 years we have gotten to the point where we are starting to understand the structural biology of amyloid fibres and how to inhibit them and how to interfere with them," Eisenberg said. "The next step is to make practical molecules that inhibit and break amyloid fibres - that is the ultimate goal."
Co-authors on this UCLA research included Kym Faull, professor of psychiatry and biobehavioural sciences; Jorge Barrio, professor of molecular and medical pharmacology; researchers Michael Sawaya and Jie Liu; postdoctoral scholars Meytal Landau, Lin Jiang and Stuart Sievers; and graduate student Arthur Laganowsky.
UCLA is California's largest university, with an enrolment of more than 38 000 undergraduate and graduate students. The UCLA College of Letters and Science and the university's 11 professional schools feature renowned faculty and offer 328 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Six alumni and five faculty have been awarded the Nobel Prize.
Source: UCLA
